GOBIOM UPDATES | MARCH 2021
Excelra’s GOBIOM is a comprehensive biomarker database comprising exploratory, preclinical and clinical biomarker intelligence. By providing critical insights into diagnosis, prognosis, treatment response, safety, efficacy and toxicity; GOBIOM facilitates data driven clinical and therapeutic decision making to accelerate drug development.
GOBIOM data coverage
The GOBIOM database is meticulously curated by our team of scientific experts who excerpt, enhance, and enrich biomarker data from various sources into a cutting-edge curation application. A variety of biomarker datasets encompassing experimental, pre-clinical, clinical, pharmacological and non-pharmacological, and treatment outcomes is captured using controlled vocabulary and ontologies.
Figure 1: GOBIOM Database – Statistical Highlights
Figure 2 (a): GOBIOM Database- Biomarker coverage by Nature
Figure 2 (b): GOBIOM Database- Biomarker coverage by Utility
Figure 2 (c): GOBIOM Database- Biomarker coverage by Study Population
Figure 3: GOBIOM statistics on new biomarkers added (Nov'20-Jan'21)
GOBIOM provides information on proteomic, genomic, biochemical, imaging, physiological, clinical scoring scales and cellular biomarkers across 18 different therapeutic areas, covering over 6000 therapeutic indications. Below are the statistics on the updated biomarkers by their nature.
Figure 4: Biomarker statistics by nature
Biomarker data is curated and mapped to their reported utilities like diagnosis, prognosis, disease progression, treatment response, surrogate, efficacy, susceptibility/risk of disease and safety/toxicity. Below are the statistics on the updated biomarkers by their application.
Figure 5: Biomarker statistics by application
GOBIOM is updated on a fortnightly basis with latest biomarker data for indications across different therapeutic areas. Below are the highlights of indications updated by biomarker counts
Figure 6: Top indications by number of biomarkers updated
The GOBIOM database is composed of many different types of content, from scientific literature to publicly available datasets which include:
- Clinical Trial Registries
- Journals Scientific Reviews
- FDA/EMEA Reports
- Company Websites
- Public Sources
The content in GOBIOM is assessed and selected for indexing based on the information it covers, such as experimental, pre-clinical, clinical, pharmacological & non-pharmacological, and treatment outcomes coverage. Records identified for indexing, are manually curated and reviewed by a team of scientific experts, trained in translational science. The processed records are enriched using a set of controlled vocabulary and ontologies to standardize and create a relational data model connecting biomarkers to diseases & drugs.